Despite initial teething problems, the number of clinically effective monoclonal antibodies is growing.
References
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Carson, D.A. et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275–311 (1986).
Morrison, S.L. et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851–6855 (1984).
Boulianne, G.L. et al. Production of functional chimaeric mouse/human antibody. Nature 312, 643–646 (1984).
Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).
Reichert, J.M. New biopharmaceuticals in the USA: trends in development and marketing approvals 1995–1999. Trends Biotechnol. 18, 364–369 (2000).
DiMasi, J. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297–307 (2001).
Fox, S. Biopharmaceutical contract manufacturing: meeting increased demand for capacity. (HighTech Business Decisions, Moraga, CA; 2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reichert, J. Monoclonal antibodies in the clinic. Nat Biotechnol 19, 819–822 (2001). https://doi.org/10.1038/nbt0901-819
Issue Date:
DOI: https://doi.org/10.1038/nbt0901-819
- Springer Nature America, Inc.
This article is cited by
-
Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
Cell & Bioscience (2019)
-
A Rational Approach for Creating Peptides Mimicking Antibody Binding
Scientific Reports (2019)
-
Equipment characterization to mitigate risks during transfers of cell culture manufacturing processes
Cytotechnology (2016)
-
Implementing high-temperature short-time media treatment in commercial-scale cell culture manufacturing processes
Applied Microbiology and Biotechnology (2014)
-
Structural basis of immunosuppression by the therapeutic antibody daclizumab
Cell Research (2010)